VYGR News and Press, Voyager Therapeutics Inc. From 01/02/24

- Collaboration with gene therapy leader Novartis aims to discover and develop new approaches for Huntington’s disease and spinal muscular atrophy - - Voyager to receive up-front consideration of $100 million and is eligible to receive milestone payments and tiered royalties - ...

2023-12-29 12:35:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2023-12-17 12:03:57 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips With so many innovative firms skyrocketing this year, astute investors seeking compelling discounts may want to turn their attention to undervalued biotech picks. Just like advancements in the ...

LEXINGTON, Mass., Dec. 06, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced that it has selected a lead development candidate for its superoxide dismutase 1 (SOD1)-muta...

2023-12-04 08:01:49 ET Summary Voyager Therapeutics is a biotech firm focused on gene therapy treatments for CNS diseases, with preclinical trials for Parkinson's, ALS, and Alzheimer's. The company's TRACER platform allows for the delivery of therapeutic genes to previously inacce...

2023-11-06 20:26:06 ET Voyager Therapeutics, Inc. (VYGR) Q3 2023 Results Conference Call November 06, 2023 04:30 PM ET Company Participants Pete Pfreundschuh - CFO Dr. Al Sandrock - CEO Dr. Todd Carter - Chief Scientific Officer Conference Call Participants...

2023-11-06 16:22:13 ET More on Voyager Therapeutics Assessing Voyager's Alzheimer's Treatment Potential Seeking Alpha’s Quant Rating on Voyager Therapeutics Historical earnings data for Voyager Therapeutics Financial information for Voyager Therapeutic...

- GLP toxicology studies initiated for VY-TAU01 anti-tau antibody for Alzheimer’s disease to enable anticipated 1H 2024 IND filing - - SOD1 ALS gene therapy program on track for development candidate selection by end of year – - Conference call at 4:30 p.m. ET toda...

CGG ADR (CGGYY) is expected to report for quarter end 2023-09-30 ATI Physical Therapy Inc. Class A (ATIP) is expected to report $-4.08 for Q3 2023 Riot Platforms Inc. (RIOT) is expected to report $-0.29 for Q3 2023 Bain Capital Specialty Finance Inc. (BCSF) is expected to report $0.57...

Voyager Therapeutics Inc. (VYGR) is expected to report $-0.58 for Q3 2023